1. Wang X, Liu R, Ma B, Yang K, Tian J, Jiang L, Bai ZG, Hao XY, Wang J, Li J. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database Syst Rev 2010;CD007563.
2. Hakim A, Lin P, Wilczynski S, Nguyen K, Lynes B, Wakabayashi M. Indications and efficacy of the human papillomavirus vaccine. Curr Treat Options in Oncol. 2010;8:393–401.
3. IARC GSmfMNiwefenmfbm, using a set of age-, sex and site-specific incidence mortality ratios obtained by the aggregation of recorded cancer registry data from Cuba, Costa Rica and Puerto Rico. For further details refer to http://globocan.iarc.fr/DataSource_and_methods.asp and http://globocan.iarc.fr/method/method.asp?country=484 ) [Accesed September 15, 2010].
4. Eltahir HA, Elhassan AM, Ibrahim ME. Contribution of retinoblastoma LOH and the p53 Arg/Pro polymorphism to cervical cancer. Mole Med Rep. 2012;6:473–6.
5. Manavi M, Hudelist G, Fink-Retter A, Gschwandtler-Kaulich D, Pischinger K, Czerwenka K. Gene profiling in pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. Gynecol Oncol. 2007;105:418–26.